Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lucid Diagnostics (LUCD) EPS (Weighted Average and Diluted) (2022 - 2025)

Lucid Diagnostics filings provide 4 years of EPS (Weighted Average and Diluted) readings, the most recent being -$0.1 for Q3 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) rose 60.0% to -$0.1 in Q3 2025 year-over-year; TTM through Sep 2025 was -$0.88, a 22.12% increase, with the full-year FY2024 number at -$1.05, up 16.67% from a year prior.
  • EPS (Weighted Average and Diluted) hit -$0.1 in Q3 2025 for Lucid Diagnostics, down from -$0.08 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.08 in Q2 2025 to a low of -$0.52 in Q1 2025.
  • Median EPS (Weighted Average and Diluted) over the past 4 years was -$0.31 (2023), compared with a mean of -$0.3.
  • The widest YoY moves for EPS (Weighted Average and Diluted): up 65.22% in 2025, down 30.0% in 2025.
  • Lucid Diagnostics' EPS (Weighted Average and Diluted) stood at -$0.4 in 2022, then soared by 37.5% to -$0.25 in 2023, then rose by 28.0% to -$0.18 in 2024, then surged by 44.44% to -$0.1 in 2025.
  • The last three reported values for EPS (Weighted Average and Diluted) were -$0.1 (Q3 2025), -$0.08 (Q2 2025), and -$0.52 (Q1 2025) per Business Quant data.